Erebagen’s new approaches to drug discovery.

£2 million IAA award supports critical early-stage translation of research.

An Impact Acceleration Account (IAA) project at the University of Warwick supported the development of a new natural product discovery company, Erebagen.  Erebagen’s platform combines bioinformatics and synthetic biology to discover new medicines and agrochemicals much more efficiently.

The initial IAA project, which helped establish Erebagen’s business plan, was followed by a broad range of other support from the innovation ecosystem. Erebagen has gone on to access further funding to continue to develop the company and skills needed, from:

  • Innovate UK’s ICURe
  • Biotechnology and Biological Sciences Research Council (BBSRC) Pathfinder and follow-on funding
  • Royal Society of Edinburgh-BBSRC Enterprise Fellowship
  • local and institutional support.

They have now filed their initial patent and attracted significant venture capital investment.

The Impact Acceleration Account (IAA) supports critical early-stage translation of UK research to real impacts.

You can read more about Erebagen in our case study here.

For further information: Contact[email protected]

Make An Enquiry.